The project seeks to identify new biomarkers for Alzheimer’s disease through the “SysPharmAD” project, awarded 1.3 million euros by the European Research Council through a Consolidator Grant. Over the next five years, until 2019, this project aims to monitor the onset and progression of Alzheimer’s disease from its most early stages and to discover new therapeutic targets and chemical compounds able to alter the biology of the disease.